The five-year relative survival rate for patients with advanced NSCLC is about 18%.[17] Therefore, the present study considers a prospective, randomised, multicentre, open-label trial that intends to investigate the clinical safety and efficacy of nazartinib in patients experiencing histologically diagnosed EGFR-mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.